RABL6

Summary

RABL6 (RAB, member RAS oncogene family like 6, HGNC:24703) is a protein-coding gene on chromosome 9q34.3, encoding Rab-like protein 6 (Q3YEC7). Small GTPase involved in the regulation of cell growth and survival.

This gene encodes a member of the Ras superfamily of small GTPases. The encoded protein binds to both GTP and GDP and may play a role in cell growth and survival. Overexpression of this gene may play a role in breast cancer tumorigenesis, and pseudogenes of this gene are located on the long arm of chromosome 2 and the short arm of chromosome 18. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 55684 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Limited, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 216 total
• Druggable target: yes
• MANE Select transcript: NM_024718

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24703
Approved symbol	RABL6
Name	RAB, member RAS oncogene family like 6
Location	9q34.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10101, FLJ13045, pp8875, bA216L13.9, Parf, RBEL1
Ensembl gene	ENSG00000196642
Ensembl biotype	protein_coding
OMIM	610615
Entrez	55684

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 9 protein_coding, 2 retained_intron, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000311502, ENST00000357466, ENST00000371663, ENST00000371671, ENST00000435930, ENST00000436380, ENST00000461992, ENST00000464941, ENST00000466096, ENST00000484471, ENST00000629216, ENST00000913422, ENST00000913423, ENST00000913424

RefSeq mRNA: 3 — MANE Select: NM_024718 NM_001173988, NM_001173989, NM_024718

CCDS: CCDS48058, CCDS55352, CCDS55353

Canonical transcript exons

ENST00000311502 — 15 exons

Exon	Start	End
ENSE00003510389	136840322	136841187
ENSE00003657895	136832265	136832370
ENSE00003792013	136835742	136835845
ENSE00003792464	136829393	136829484
ENSE00003792609	136839694	136839865
ENSE00003792922	136837862	136838015
ENSE00003794042	136831721	136831861
ENSE00003795592	136823525	136823659
ENSE00003795632	136837346	136837662
ENSE00003795867	136825779	136825826
ENSE00003795926	136840154	136840212
ENSE00003797983	136838909	136839121
ENSE00003799048	136828494	136828546
ENSE00003800391	136839222	136839486
ENSE00003849626	136807948	136808326

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 98.17.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 83.9612 / max 654.4916, expressed in 1827 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
99558	83.9612	1827

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	98.17	gold quality
cerebellar hemisphere	UBERON:0002245	98.03	gold quality
cerebellar cortex	UBERON:0002129	97.95	gold quality
nucleus accumbens	UBERON:0001882	97.26	gold quality
apex of heart	UBERON:0002098	97.15	gold quality
right frontal lobe	UBERON:0002810	97.01	gold quality
anterior cingulate cortex	UBERON:0009835	96.56	gold quality
cerebellum	UBERON:0002037	96.52	gold quality
gastrocnemius	UBERON:0001388	96.49	gold quality
cingulate cortex	UBERON:0003027	96.44	gold quality
caudate nucleus	UBERON:0001873	96.29	gold quality
hindlimb stylopod muscle	UBERON:0004252	96.12	gold quality
pylorus	UBERON:0001166	96.02	gold quality
amygdala	UBERON:0001876	95.92	gold quality
mucosa of transverse colon	UBERON:0004991	95.91	gold quality
body of pancreas	UBERON:0001150	95.85	gold quality
adenohypophysis	UBERON:0002196	95.83	gold quality
muscle of leg	UBERON:0001383	95.77	gold quality
putamen	UBERON:0001874	95.67	gold quality
sural nerve	UBERON:0015488	95.40	gold quality
pituitary gland	UBERON:0000007	95.31	gold quality
transverse colon	UBERON:0001157	95.26	gold quality
lower esophagus mucosa	UBERON:0035834	95.19	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.18	gold quality
body of stomach	UBERON:0001161	95.06	gold quality
renal medulla	UBERON:0000362	94.73	gold quality
fundus of stomach	UBERON:0001160	94.70	gold quality
lower esophagus	UBERON:0013473	94.64	gold quality
lower esophagus muscularis layer	UBERON:0035833	94.64	gold quality
right atrium auricular region	UBERON:0006631	94.53	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-7052	yes	36.64
E-ANND-3	yes	9.34

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

17 targeting RABL6, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-486-3P	99.51	66.82	1901
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-125A-5P	99.36	70.59	1640
HSA-MIR-125B-5P	99.36	70.36	1662
HSA-MIR-4284	99.36	65.25	1293
HSA-MIR-504-3P	99.30	67.18	1745
HSA-MIR-5088-3P	98.29	66.63	1310
HSA-MIR-6882-3P	98.23	67.01	1119
HSA-MIR-122-5P	97.23	64.92	1024
HSA-MIR-4433B-3P	97.22	63.62	663
HSA-MIR-2861	95.24	65.47	1056
HSA-MIR-12115	94.19	66.37	738
HSA-MIR-10392-3P	88.79	61.83	122

Literature-anchored findings (GeneRIF, showing 11)

• RBEL1A and RBEL1B are novel Rab-like proteins that localize in the nucleus and cytosol and may play an important role in breast tumorigenesis (PMID:17962191)
• characterization of all four RBEL1 splice variants in terms of their GTPase activities, subcellular localizations, regulations & potential functions; results indicate RBEL1 proteins are linked to cell growth & survival & possess unique characteristics (PMID:19433581)
• RBEL1A appears to function as a novel p53 negative regulator that facilitates MDM2-dependent p53 ubiquitylation and degradation. (PMID:23572512)
• Breast cancer patients with high levels of C9orf86 expression showed a significant trend towards worse survival compared to patients with low C9orf86 expression. (PMID:23977139)
• work identifies RABL6A as a novel negative regulator of Rb1 (PMID:25273089)
• Rb knockdown reversed RBEL1 depletion-induced tumor suppressive effects. In conclusion, the present results suggest that RBEL1 modulates cell proliferation and G1S transition by inhibiting Rb in osteosarcoma (PMID:26676380)
• The present work identifies RABL6A as a new inhibitor of the PP2A tumor suppressor and an essential activator of AKT in PNET cells. Our findings offer what we believe is a novel strategy of PP2A reactivation for treatment of PNETs as well as other human cancers driven by RABL6A overexpression and PP2A inactivation. (PMID:30721156)
• RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors. (PMID:32086342)
• High expression of RABL6 promotes cell proliferation and predicts poor prognosis in esophageal squamous cell carcinoma. (PMID:32600359)
• RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner. (PMID:34065204)
• CircTMC5 promotes gastric cancer progression and metastasis by targeting miR-361-3p/RABL6. (PMID:34296378)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	rabl6b	ENSDARG00000077653
danio_rerio	rabl6a	ENSDARG00000079046
danio_rerio		ENSDARG00000115005
mus_musculus	Rabl6	ENSMUSG00000015087
rattus_norvegicus	Rabl6	ENSRNOG00000016795
caenorhabditis_elegans		WBGENE00008585

Protein

Protein identifiers

Rab-like protein 6 — Q3YEC7 (reviewed: Q3YEC7)

Alternative names: GTP-binding protein Parf, Partner of ARF, Rab-like protein 1

All UniProt accessions (4): Q3YEC7, F2Z2T0, G3V154, H0Y7H6

UniProt curated annotations — full annotation on UniProt →

Function. Small GTPase involved in the regulation of cell growth and survival. Promotes cellular proliferation. May reduce growth inhibitory activity of CDKN2A.

Subcellular location. Cytoplasm Nucleus.

Post-translational modifications. Isoform 1 is O-glycosylated, while other isoforms are not.

Miscellaneous. Predominant isoform. Overexpressed in about 67% of primary breast tumors.

Similarity. Belongs to the small GTPase superfamily. Rab family.

Isoforms (6)

UniProt ID	Names	Canonical?
Q3YEC7-1	1, RBEL1A	yes
Q3YEC7-2	2
Q3YEC7-3	3, RBEL1B
Q3YEC7-4	4, RBEL1D
Q3YEC7-5	5
Q3YEC7-6	6, RBEL1C

RefSeq proteins (3): NP_001167459, NP_001167460, NP_078994* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR040385	RABL6	Family

Pfam: PF08477

Catalyzed reactions (Rhea), 1 shown:

• GTP + H2O = GDP + phosphate + H(+) (RHEA:19669)

UniProt features (49 total): modified residue 13, compositionally biased region 11, binding site 11, splice variant 6, region of interest 5, chain 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q3YEC7-F1	60.84	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (11): 55; 56; 57; 57; 70; 75; 75; 100; 176; 179; 215

Post-translational modifications (13): 1, 402, 425, 427, 470, 471, 492, 525, 577, 596, 599, 640, 641

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 97 (showing top): RNGTGGGC_UNKNOWN, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, AREB6_01, YY1_Q6, FOXD3_01, E2F_Q3, YY1_02, HFH8_01, E4F1_Q6, LIAO_METASTASIS, HFH1_01, NKX22_01, OUYANG_PROSTATE_CANCER_PROGRESSION_DN, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, E2F1_Q3

GO Biological Process (0):

GO Molecular Function (5): G protein activity (GO:0003925), GTP binding (GO:0005525), nucleotide binding (GO:0000166), GTPase activity (GO:0003924), protein binding (GO:0005515)

GO Cellular Component (6): nucleus (GO:0005634), cytoplasm (GO:0005737), centrosome (GO:0005813), cytosol (GO:0005829), centriolar satellite (GO:0034451), ciliary basal body (GO:0036064)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
microtubule organizing center	2
GTPase activity	1
molecular function regulator activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
ribonucleoside triphosphate phosphatase activity	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
centriole	1
cytoplasm	1
centrosome	1
cilium	1

Protein interactions and networks

STRING

1853 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RABL6	TBRG1	Q3YBR2	774
RABL6	CCDC183	Q5T5S1	625
RABL6	CDKN2AIP	Q9NXV6	624
RABL6	CDKN2A	P42771	617
RABL6	RABL3	Q5HYI8	569
RABL6	CCDC138	Q96M89	489
RABL6	VPS50	Q96JG6	489
RABL6	NPM1	P06748	465
RABL6	DPP7	Q9UHL4	452
RABL6	CCDC186	Q7Z3E2	447
RABL6	NUPR1	O60356	444
RABL6	RABGGTA	Q92696	440
RABL6	LCN9	Q8WX39	383
RABL6	TTLL11	Q8NHH1	383
RABL6	RAB3IP	Q96QF0	380

IntAct

76 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
AP3M1	AP3B1	psi-mi:“MI:0914”(association)	0.640
SPINK7	RABL6	psi-mi:“MI:0915”(physical association)	0.550
AP3S1	AP3B1	psi-mi:“MI:0914”(association)	0.530
HDGFL2	CDC7	psi-mi:“MI:0914”(association)	0.530
MDFI	RABL6	psi-mi:“MI:0915”(physical association)	0.510
RABL6	MDFI	psi-mi:“MI:0915”(physical association)	0.510
DDX21	MED19	psi-mi:“MI:2364”(proximity)	0.480
	AP3D1	psi-mi:“MI:0914”(association)	0.460
RABL6	CHD4	psi-mi:“MI:0915”(physical association)	0.400
RABL6	H1-4	psi-mi:“MI:0915”(physical association)	0.400
RABL6	DNAJC3	psi-mi:“MI:0915”(physical association)	0.400
ECE1	RABL6	psi-mi:“MI:0915”(physical association)	0.370
RABL6	BRME1	psi-mi:“MI:0915”(physical association)	0.370
CALCOCO2	RABL6	psi-mi:“MI:0915”(physical association)	0.370
RBPMS	RABL6	psi-mi:“MI:0915”(physical association)	0.370
Bub1b	ASAH1	psi-mi:“MI:0914”(association)	0.350
Mis12		psi-mi:“MI:0914”(association)	0.350
CDC42	BBX	psi-mi:“MI:0914”(association)	0.350
RACGAP1	STX18	psi-mi:“MI:0914”(association)	0.350
ZWINT	ARHGAP32	psi-mi:“MI:0914”(association)	0.350
Ercc6l	RPL17	psi-mi:“MI:0914”(association)	0.350
NAF1	C1orf226	psi-mi:“MI:0914”(association)	0.350

BioGRID (161): RABL6 (Affinity Capture-RNA), RABL6 (Affinity Capture-RNA), MDM2 (Affinity Capture-Western), C19orf57 (Two-hybrid), RABL6 (Affinity Capture-MS), RABL6 (Affinity Capture-MS), RABL6 (Affinity Capture-MS), RABL6 (Affinity Capture-MS), RABL6 (Two-hybrid), RABL6 (Two-hybrid), RABL6 (Two-hybrid), RABL6 (Affinity Capture-Western), RABL6 (Affinity Capture-MS), RABL6 (Proximity Label-MS), RABL6 (Proximity Label-MS)

ESM2 similar proteins: A0A088MLT8, A0A0G2K0D3, A2AQ19, B3KU38, D3ZTQ1, E1BTG2, E6ZGB4, E9PSK7, O35274, O60271, O75151, O75376, P12755, P22682, P29536, P49140, Q08DA0, Q13191, Q3B7T9, Q3TTA7, Q3UHZ5, Q3USH5, Q3YEC7, Q4KKX4, Q58A65, Q5SFM8, Q5U3K5, Q60698, Q60974, Q62415, Q640N2, Q6P5Q4, Q6R891, Q70E73, Q80XA6, Q86YP4, Q8BVA4, Q8CHY6, Q8K4S7, Q8R3Y5

Diamond homologs: Q08DA0, Q3YEC7, Q5U3K5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

216 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	166
Likely benign	22
Benign	8

Top pathogenic / likely-pathogenic (0)

SpliceAI

3100 predictions. Top by Δscore:

Variant	Effect	Δscore
9:136808311:G:GT	donor_gain	1.0000
9:136808327:G:GG	donor_gain	1.0000
9:136823516:C:CA	acceptor_gain	1.0000
9:136823522:CAG:C	acceptor_loss	1.0000
9:136823523:A:AG	acceptor_gain	1.0000
9:136823523:A:G	acceptor_loss	1.0000
9:136823523:AGT:A	acceptor_gain	1.0000
9:136823524:G:GA	acceptor_gain	1.0000
9:136823524:GT:G	acceptor_gain	1.0000
9:136823524:GTG:G	acceptor_gain	1.0000
9:136823524:GTGA:G	acceptor_gain	1.0000
9:136823524:GTGAA:G	acceptor_gain	1.0000
9:136823655:CAAGA:C	donor_gain	1.0000
9:136823656:AAGA:A	donor_gain	1.0000
9:136823657:AGA:A	donor_gain	1.0000
9:136823658:GA:G	donor_gain	1.0000
9:136823658:GAG:G	donor_gain	1.0000
9:136823659:AG:A	donor_loss	1.0000
9:136823660:G:GG	donor_gain	1.0000
9:136823660:G:T	donor_loss	1.0000
9:136823664:GTGTG:G	donor_gain	1.0000
9:136825777:A:AG	acceptor_gain	1.0000
9:136825778:G:GG	acceptor_gain	1.0000
9:136825824:AAGGT:A	donor_loss	1.0000
9:136825827:G:GA	donor_loss	1.0000
9:136828491:AAG:A	acceptor_gain	1.0000
9:136828492:A:G	acceptor_gain	1.0000
9:136829387:CCCCA:C	acceptor_loss	1.0000
9:136829388:CCCAG:C	acceptor_loss	1.0000
9:136829389:CCA:C	acceptor_loss	1.0000

AlphaMissense

4777 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:136823531:T:A	I46K	1.000
9:136823542:G:A	G50R	1.000
9:136823542:G:C	G50R	1.000
9:136823543:G:A	G50E	1.000
9:136823543:G:T	G50V	1.000
9:136823558:G:A	G55D	1.000
9:136823582:T:C	L63P	1.000
9:136823647:T:A	W85R	1.000
9:136823647:T:C	W85R	1.000
9:136825806:T:A	V98D	1.000
9:136825808:T:A	W99R	1.000
9:136825808:T:C	W99R	1.000
9:136829479:G:C	K151N	1.000
9:136829479:G:T	K151N	1.000
9:136832321:G:A	G219D	1.000
9:136832366:T:C	L234P	1.000
9:136835764:T:C	L243P	1.000
9:136808302:T:C	F36L	0.999
9:136808303:T:C	F36S	0.999
9:136808303:T:G	F36C	0.999
9:136808304:C:A	F36L	0.999
9:136808304:C:G	F36L	0.999
9:136808306:C:A	A37D	0.999
9:136808311:G:A	G39R	0.999
9:136808311:G:C	G39R	0.999
9:136808311:G:T	G39W	0.999
9:136808320:T:G	Y42D	0.999
9:136808325:C:A	N43K	0.999
9:136808325:C:G	N43K	0.999
9:136823531:T:G	I46R	0.999

dbSNP variants (sampled 300 via entrez): RS1000102818 (9:136826736 G>A), RS1000126799 (9:136829595 G>A), RS1000181719 (9:136829839 C>T), RS1000211335 (9:136829712 A>G), RS1000274682 (9:136807463 G>A,C,T), RS1000356824 (9:136822508 G>C,T), RS1000412325 (9:136822745 A>G), RS1000464160 (9:136822859 C>A,T), RS1000556063 (9:136825674 G>A), RS1000615416 (9:136817244 C>T), RS1000720128 (9:136811540 C>G,T), RS1000769206 (9:136811824 G>A), RS1000842532 (9:136840166 A>C,G), RS1000881418 (9:136806278 T>A,C), RS1001060441 (9:136811045 A>C)

Disease associations

OMIM: gene MIM:610615 | disease phenotypes: MIM:156000

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Limited	Autosomal recessive

Mondo (2): Meniere disease (MONDO:0007972), neurodevelopmental disorder (MONDO:0700092)

Orphanet (1): NON RARE IN EUROPE: Menière disease (Orphanet:45360)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002932_15	Manganese levels	8.000000e-06

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008575	Meniere Disease	C09.218.568.217.500
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067258 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.81	Kd	155	nM	CHEMBL5653589
6.81	ED50	155	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149182: Binding affinity to human RABL6 incubated for 45 mins by Kinobead based pull down assay	kd	0.1550	uM

CTD chemical–gene interactions

45 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, decreases expression, increases expression	4
perfluoro-n-nonanoic acid	decreases expression	2
Particulate Matter	affects cotreatment, increases abundance, increases expression	2
FR900359	affects phosphorylation	1
bisphenol F	increases expression	1
biochanin A	decreases expression	1
bisphenol A	increases expression	1
lead acetate	increases expression	1
butyraldehyde	decreases expression	1
perfluorooctanoic acid	decreases expression	1
cupric chloride	increases expression	1
coumarin	affects phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
perfluorohexanesulfonic acid	decreases expression	1
bisphenol B	increases expression	1
bisphenol Z	increases expression	1
LDN 193189	affects cotreatment, increases expression	1
NSC 689534	affects binding, decreases expression	1
Vorinostat	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Arsenic	affects methylation	1
Vehicle Emissions	increases abundance, increases expression	1
Caffeine	affects phosphorylation	1
Cannabidiol	decreases expression	1
Carbamazepine	affects expression	1
Copper	affects binding, decreases expression	1
Dimethyl Sulfoxide	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652224	Binding	Binding affinity to human RABL6 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E0MG	Ubigene HeLa RABL6 KO	Cancer cell line	Female
CVCL_E0YH	Ubigene MCF-7 RABL6 KO	Cancer cell line	Female

Clinical trials (associated diseases)

233 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT01574313	PHASE4	COMPLETED	Effect of Stellate Ganglion Block on Meniere’s Disease
NCT02529475	PHASE4	TERMINATED	Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS)
NCT04815187	PHASE4	ACTIVE_NOT_RECRUITING	Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere’s Disease
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT03664674	PHASE3	COMPLETED	Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere’s Disease
NCT04677972	PHASE3	COMPLETED	SPI-1005 for the Treatment of Meniere’s Disease
NCT05851508	PHASE3	RECRUITING	The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Placebo in the Treatment of Vertigo Attacks in Meniere’s Disease
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT05420350	PHASE2	UNKNOWN	Lamotrigine and Bupropion for Meniere’s Disease
NCT06544434	PHASE2	RECRUITING	Laser Acupuncture for Meniere Disease
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT04674735	PHASE1	WITHDRAWN	Safety of APSLXR in Patients Presenting Vertigo of Vestibular Origin or Meniere’s Disease
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum